CARGO Therapeutics (CRGX) Q1 2025 earnings summary

Executive summary

• Discontinued lead program firi-cel and suspended pipeline development, resulting in workforce reductions of 50% in January and an additional 90% in March 2025, as part of a strategic review to explore alternatives such as reverse merger, business combination, or cash sale.

• Engaged TD Cowen as exclusive financial advisor to evaluate strategic options; no assurance of transaction completion.

• Pipeline includes CRG-023, a tri-specific CAR T candidate, and a novel allogeneic platform, but all development efforts are currently suspended.

Financial highlights

• Net loss of $84.5 million for Q1 2025, compared to $35.8 million for Q1 2024, driven by $46.3 million in restructuring, impairment, and suspended program costs.

• Operating expenses rose to $88.4 million from $40.8 million year-over-year, mainly due to restructuring charges.

• Cash, cash equivalents, and marketable securities totaled $331.3 million as of March 31, 2025.

• Interest income decreased to $3.9 million from $5.0 million year-over-year due to lower average marketable securities balances.

• Accumulated deficit reached $397.1 million as of March 31, 2025.

Outlook and guidance

• Existing cash and marketable securities expected to fund operations through mid-2028 based on current projections and reduced operating expenses.

• Operating expenses anticipated to decrease further due to workforce reductions and suspended development.

• Ongoing review of strategic alternatives may result in significant additional costs regardless of transaction outcome.